Last reviewed 2026-04-22 · How we verify

EVARREST™

EVARREST is a topical hemostatic agent that combines thrombin and fibrinogen to form a stable clot at the surgical site.

EVARREST is a topical hemostatic agent that combines thrombin and fibrinogen to form a stable clot at the surgical site. Used for Hemostasis in surgical procedures where bleeding control is needed.

At a glance

Mechanism of action

EVARREST is a composite hemostatic patch containing human thrombin and human fibrinogen that works by mimicking the final steps of the coagulation cascade. When applied to bleeding surfaces, the thrombin activates fibrinogen to form fibrin, creating a stable clot that adheres to the tissue. This provides rapid hemostasis without requiring systemic absorption.

Approved indications

• Hemostasis in surgical procedures where bleeding control is needed

Common side effects

• Allergic reaction
• Infection at application site
• Hematoma

Key clinical trials

• Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer (PHASE1, PHASE2)
• Fibrin Glue After ESD for High Risk Patients of Bleeding (NA)
• The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study (PHASE3)
• Topical Raplixa for Surgical Bleeding in Children (PHASE2)
• NuTech Affinity™ for the Treatment of Chondral Defects (NA)
• A Study of Fibrocaps™ in Surgical Bleeding (PHASE3)
• A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy (NA)
• The Fibrin Pad Cardiovascular Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.